FDA grants priority review to Gilead Sciences’ hepatitis C combination drug
Gilead filed a new drug application for the treatment, a combination of the company’s Sovaldi with velpatasvir, in October last year. A final decision from the FDA is
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
The companies have signed a collaboration agreement under which Pfizer and Merck will combine their avelumab cancer drug with Syndax’s entinostat, a treatment currently being studied in patients
This new strategic collaboration is expected to leverage the expertise of Araim Pharmaceuticals in scientific discovery and research with Vault Bioventures’ proven capability in clinical and regulatory development
Preeclampsia is one of the most common medical complications of pregnancy, and a leading cause of premature births, stillbirths and early neonatal and maternal deaths. Severe preeclampsia occurs